HAL (France)
open access
ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML
Acute myeloid leukemia (AML) treatments often cause profound immunosuppression, limiting immune-mediated control of residual disease. DIMATE, an ALDH1 inhibitor under clinical evaluation, induces aldehyde and redox stress in leukemic cells, but its impact on immune effector functions and tumor immun
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)#1378975
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL#1095659
- Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia#28562
- Melatonin overcomes ABCB1- mediated cancer multidrug resistance by modulating mitochondrial activity#345554
- CLL-IMPACT: A Clinical Nutrition Trial Investigating Immune and Metabolic Changes in Early-Stage CLL#810575
Record · ID 1425838
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive